Literature DB >> 22717669

Successful treatment with a low-dose cisplatin--etoposide regimen for patients with diencephalic syndrome.

Iacopo Sardi1, Cecilia Bresci, Elisabetta Schiavello, Veronica Biassoni, Valentina Fratoni, Stefania Cardellicchio, Lorenzo Genitori, Maurizio Aricò, Maura Massimino.   

Abstract

Diencephalic syndrome (DS) is a rare but rapidly fatal condition, usually occurring during the first year of life, as a result of a hypothalamic/chiasmatic tumor. The purpose of this study was to induce an objective tumor response and to achieve rapid weight recovery by using ten three-day courses of reduced-dose cisplatin-etoposide. Between 2004 and 2009, eight pediatric patients with DS as a result of an hypothalamic tumor and with a median age at diagnosis of 6.5 months (range 4-60 months) received 10 monthly courses of cisplatin (25 mg/m(2)/day on days 1-3) and etoposide (100 mg/m(2)/day on days 1-3). Under chemotherapy, rapid weight recovery was observed for all patients; tumor response was observed for six (75 %; partial response in four and minimum response in two). The other two had stable disease at completion of treatment. Mean time to weight recovery was 6 months (range 5-7 months) for pilomyxoid astrocytoma patients, and 3.3 months (range 3-4 months) for those with pilocytic astrocytoma. For DS patients who received nutritional support (enteral or parenteral nutrition) the mean time for weight recovery was 5 months (range 3-7 months) whereas children who were able to orally ingest a high-energy diet had a mean time for weight recovery of 8.66 months (range 3-19 months). After follow-up ranging from 22 to 89 months (median 38 months) all patients are alive. A low-dose cisplatin-etoposide regimen is highly effective regarding tumor response and treatment of DS symptoms/cachexia without causing significant side-effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717669     DOI: 10.1007/s11060-012-0903-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Optic pathway hypothalamic gliomas in children under three years of age: the role of chemotherapy.

Authors:  M M Silva; S Goldman; G Keating; M A Marymont; J Kalapurakal; T Tomita
Journal:  Pediatr Neurosurg       Date:  2000-09       Impact factor: 1.162

2.  Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital.

Authors:  A Gajjar; R A Sanford; R Heideman; J J Jenkins; A Walter; Y Li; J W Langston; M Muhlbauer; J M Boyett; L E Kun
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

3.  Diencephalic cachexia of infancy: Russell's syndrome.

Authors:  Anne-Marie Murphy; Brendan Drumm; Clare Brenner; Sally Ann Lynch
Journal:  Clin Dysmorphol       Date:  2006-10       Impact factor: 0.816

4.  A 4-month-old boy with severe emaciation, normal linear growth, and a happy affect.

Authors:  D Greenes; M Woods
Journal:  Curr Opin Pediatr       Date:  1996-02       Impact factor: 2.856

Review 5.  Central nervous system mechanisms contributing to the cachexia-anorexia syndrome.

Authors:  C R Plata-Salamán
Journal:  Nutrition       Date:  2000-10       Impact factor: 4.008

Review 6.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

7.  High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.

Authors:  Maura Massimino; Filippo Spreafico; Graziella Cefalo; Riccardo Riccardi; John David Tesoro-Tess; Lorenza Gandola; Daria Riva; Antonio Ruggiero; Laura Valentini; Elena Mazza; Lorenzo Genitori; Concezio Di Rocco; Piera Navarria; Michela Casanova; Andrea Ferrari; Roberto Luksch; Monica Terenziani; Maria Rosa Balestrini; Cesare Colosimo; Franca Fossati-Bellani
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

8.  ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology.

Authors:  J Arends; G Bodoky; F Bozzetti; K Fearon; M Muscaritoli; G Selga; M A E van Bokhorst-de van der Schueren; M von Meyenfeldt; G Zürcher; R Fietkau; E Aulbert; B Frick; M Holm; M Kneba; H J Mestrom; A Zander
Journal:  Clin Nutr       Date:  2006-05-12       Impact factor: 7.324

Review 9.  Spontaneous regression of low-grade astrocytomas in childhood.

Authors:  S M Schmandt; R J Packer; L G Vezina; J Jane
Journal:  Pediatr Neurosurg       Date:  2000-03       Impact factor: 1.162

10.  Diencephalic syndrome revisited.

Authors:  I M Burr; A E Slonim; R K Danish; N Gadoth; I J Butler
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

View more
  4 in total

Review 1.  Advances in the management of low-grade gliomas.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

2.  Favorable survival and metabolic outcome for children with diencephalic syndrome using a radiation-sparing approach.

Authors:  John-Paul Kilday; Ute Bartels; Annie Huang; Mary Barron; Mary Shago; Matthew Mistry; Nataliya Zhukova; Normand Laperriere; Peter Dirks; Cynthia Hawkins; Eric Bouffet; Uri Tabori
Journal:  J Neurooncol       Date:  2013-11-12       Impact factor: 4.130

Review 3.  Diencephalic syndrome in childhood, a challenging cause of failure to thrive: miniseries and literature review.

Authors:  Sandra Trapani; Barbara Bortone; Martina Bianconi; Chiara Rubino; Iacopo Sardi; Paolo Lionetti; Giuseppe Indolfi
Journal:  Ital J Pediatr       Date:  2022-08-17       Impact factor: 3.288

4.  An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma.

Authors:  Alessia Stival; Maurizio Lucchesi; Silvia Farina; Anna Maria Buccoliero; Francesca Castiglione; Lorenzo Genitori; Maurizio de Martino; Iacopo Sardi
Journal:  BMC Cancer       Date:  2015-09-04       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.